Quviviq
Total Payments
$618,251
Transactions
99
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $618,183 | 96 | 0 |
| 2023 | $67.92 | 3 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $618,183 | 96 | 100.0% |
| Food and Beverage | $67.92 | 3 | 0.0% |
Payments by Type
Research
$618,183
96 transactions
General
$67.92
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multi-center, Double-blind, Randomized, Placebo-controlled, 2-way Cross-over Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia | IDORSIA PHARMACEUTICALS US INC | $446,900 | 0 |
| Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder | IDORSIA PHARMACEUTICALS US INC | $162,985 | 0 |
| A Single-center, Open-label, Randomized, Crossover Phase 1 Trial to Investigate Bioequivalence Between 5 X 10 mg Tablets and 2 X 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants | IDORSIA PHARMACEUTICALS US INC | $8,299 | 0 |
Ad
Manufacturing Companies
- IDORSIA PHARMACEUTICALS US INC $618,251
Product Information
- Type Drug
- Total Payments $618,251
- Total Doctors 3
- Transactions 99
About Quviviq
Quviviq is a drug associated with $618,251 in payments to 3 healthcare providers, recorded across 99 transactions in the CMS Open Payments database. The primary manufacturer is IDORSIA PHARMACEUTICALS US INC.
Payment data is available from 2023 to 2024. In 2024, $618,183 was paid across 96 transactions to 0 doctors.
The most common payment nature for Quviviq is "Unspecified" ($618,183, 100.0% of total).
Quviviq is associated with 3 research studies, including "A Multi-center, Double-blind, Randomized, Placebo-controlled, 2-way Cross-over Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia" ($446,900).